投稿一覧に戻る アンジェス(株)【4563】の掲示板 2022/11/19〜2022/11/22 1083 本物葵ちゃん 2022年11月22日 22:15 >>1078 https://vasomune.com/vasomune-and-anges-announce-first-patient-enrolled-in-phase-2a-clinical-study-evaluating-av-001-for-the-treatment-of-severe-covid-19-disease/ January 18, 2022 08:00 AM Eastern Standard Time Originally discovered and designed at Sunnybrook Research Institute at Sunnybrook Hospital in Toronto, AV-001 is being developed by Vasomune Therapeutics, Inc. under a co-development agreement with AnGes, Inc. [TYO: 4563]. そう思う18 そう思わない7 開く お気に入りユーザーに登録する 無視ユーザーに登録する 違反報告する 証券取引等監視委員会に情報提供する ツイート 投稿一覧に戻る
>>1078
https://vasomune.com/vasomune-and-anges-announce-first-patient-enrolled-in-phase-2a-clinical-study-evaluating-av-001-for-the-treatment-of-severe-covid-19-disease/
January 18, 2022 08:00 AM Eastern Standard Time
Originally discovered and designed at Sunnybrook Research Institute at Sunnybrook Hospital in Toronto, AV-001 is being developed by Vasomune Therapeutics, Inc. under a co-development agreement with AnGes, Inc. [TYO: 4563].